Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC

Prior treatment

• Currently participating in and receiving other experimental treatments;
• Previously underwent solid organ transplantation, diagnosed with immunodeficiency;
• Bleeding from esophageal or gastric varices within 3 months prior to enrollment;
• Patients who have previously used pomalidomide or thalidomide;
• Patients who have previously received CTLA-4 in combination with PD-1/PD-L1 inhibitors;

Other illness

• Active infection requiring systemic treatment;
• Patients with myocardial ischemia or myocardial infarction graded CTCAE grade II or higher, or uncontrolled arrhythmia;

Lab values

• CTCAE grading Platelet count < 50 × 10⁹/L or neutrophil count < 1 × 10⁹/L

Other

• Fibrous plate layer or sarcomatoid HCC or mixed type HCC-ICC;
• Hepatic encephalopathy in the past 6 months, or obvious ascites at enrollment;
• Pregnant or breastfeeding women;
• Other situations deemed unsuitable for participation in this trial by researchers;

• Age ≥ 18 years old;
• Patients with hepatocellular carcinoma who previously received lenvatinib and PD-1 inhibitors and whose tumors progressed on imaging (enhanced MRI, enhanced CT, or PET-CT) were treated with lenalidomide；
• Expected survival period exceeding 3 months;
• Patients with a history of other malignant tumors who have been disease-free for more than 2 years after initial treatment (such as non-melanoma skin cancer or cervical carcinoma in situ);
• Participants of childbearing age agreed to use contraception during the study period;